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2883included patients present cirrhosis as a clear confounding factor for
the interpretation of the data.
Based on these 3 different aspects, hemolytic anemia was
changed into group 5 in the current classiﬁcation, until new data
support otherwise (6). It is undeniable that PH is a signiﬁcant
complication of hemolytic anemia, with strong prognostic impli-
cation and, as such, should be better understood in order to support
the use of speciﬁc treatment strategies. Such a situation also occurs
in other clinical conditions that may develop pre-capillary PH.
Sarcoidosis is a clear example of a clinical condition in which a
signiﬁcant proportion of patients may develop PH. Nevertheless,
the lack of appropriate pathological studies and treatment trials
prevent its inclusion into group 1, even considering those pre-
senting true pre-capillary PH.
The current classiﬁcation system for PH has limitations. For
instance, prevalence of each one of the forms of PH is not covered
by the current classiﬁcation system and this may overemphasize the
importance of group 1 over the other groups, and should be
considered in future reviews of the current classiﬁcation.
Nevertheless, it is important to highlight that for any speciﬁc
subform of PH, targeted therapies should be appropriately tested
instead of extrapolating the results from studies enrolling poten-
tially similar conditions. Also in this sense, hemolytic anemias, as
other clinical conditions within group 5, represent an open and
important ﬁeld for PH research.
Finally, the change in clinical classiﬁcation was proposed by 12
of the 13 members of the Task Force on Clinical Classiﬁcation and
approved by more than 85% of the attendees during the plenary
session of the 5th World Symposium held in 2013, in Nice, France.*Rogerio Souza, MD, PhD
Gerald Simonneau, MD
*Pulmonary Department, Heart Institute
University of Sao Paulo Medical School
Av. Dr. Eneas de Carvalho Aguiar 44 - 5 and Bl 2
Sao Paulo 05403-000
Brazil
E-mail: rogerio.souza@incor.usp.br
http://dx.doi.org/10.1016/j.jacc.2014.03.044
Please note: Dr. Simonneau has served on the advisory boards of Eli Lilly, Actelion,
Pﬁzer, Bayer-Schering, GlaxoSmithKline, and Novartis; received lecture fees from
Eli Lilly, Pﬁzer, Bayer-Schering, GlaxoSmithKline; and received grant support from
Actelion, Pﬁzer, Bayer-Schering, GlaxoSmithKline, and Novartis. Dr. Souza has
reported that he has no relationships relevant to the contents of this paper to disclose.REFERENCES
1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classi-
ﬁcation of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43–54.
2. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pul-
monary hypertension diagnosed by right heart catheterisation in sickle
cell disease. Eur Respir J 2012;39:112–8.
3. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in
adults with sickle cell disease and pulmonary hypertension. JAMA 2012;
307:1254–6.
4. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary
hypertension in sickle cell disease. N Engl J Med 2011;365:44–53.
5. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in
sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum
Pathol 2002;33:1037–43.
6. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classiﬁ-
cation of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34–41.The Latest Generation of
Troponin Immunoassays
The “Cholesterol” of the
Third Millennium?We read with interest the paper by White et al. (1), who reported
that both baseline troponin I levels and change at 1 year measured
with a latest-generation immunoassay are reliable predictors of
coronary heart disease, death, and myocardial infarction after
adjustment for the most important cardiovascular risk factors,
including sex, age, body mass index, diabetes, smoking, hyperten-
sion, total and high-density lipoprotein cholesterol, triglycerides,
and fasting glucose.
Since their original publication in 2002 (2) and the update in
2004 (3), the Adult Treatment Panel (ATP) III Guidelines have
represented a cornerstone for the management of high blood
cholesterol and related disorders. Although enthusiastically
awaited, the next update of this document (i.e., the ATP IV) has
not been published so far. The evidence for a substantial revision
of available recommendations is weak, however, because no
major progress has been made in the management of dyslipi-
demia in the past decade. Nevertheless, the data published
by White et al. (1), which conﬁrm previous ﬁndings from
separate investigations (4), support the notion that chronic
troponin elevations truly mirror a pathophysiological process
that is distinct from the acute increase more typically observed
in patients with myocardial infarction. Recent advances in our
understanding of the pathogenesis of ischemic heart disease
conﬁrm that the turnover of cardiospeciﬁc troponins is sub-
stantially increased in patients with coronary artery disease, and
their plasma levels signiﬁcantly correlate with the burden of
coronary atherosclerosis (5). As such, it seems now unques-
tionable that the assessment of these cardiospeciﬁc biomarkers
would provide a net incremental beneﬁt for cardiovascular risk
assessment, not only in patients with established coronary artery
disease, but also in the general population (4). While “waiting
for Godot” (i.e., the ATP IV), it seems reasonable to suggest
that the expert panel of the National Cholesterol Education
Program should not ignore the valuable information that car-
diospeciﬁc troponins may provide for the screening and pre-
vention of cardiovascular risk, especially when these biomarkers
are measured with the latest generation of highly-sensitive
immunoassays.
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1269–75.ReplyThe Latest Generation of
Troponin Immunoassays
The “Cholesterol” of the
Third Millennium?We agree with Drs. Lippi and Cervellin that troponin levels may be
useful to target treatments that reduce cardiovascular risk. In our
analysis (1), the number of patients treated with pravastatin to pre-
vent 1 coronary heart disease (CHD) death or nonfatal myocardial
infarction was 29 when troponin I was 0.18 mmol/l (the highest
tertile) compared with 39 patients with troponin I between 0.006
and <0.18 ng/ml and 52 patients in the lowest tertile with non-
detectable troponin I levels (<0.006 ng/ml) at baseline. Patients with
elevated troponin I levels were, therefore, more likely to beneﬁt from
pravastatin. However, high-intensity statins are recommended for all
patients with known CHD (2), and similar analyses have not been
performed in primary prevention trials of statins, where estimates of
cardiovascular risk are more relevant to treatment decisions.
Measuring troponins could also improve targeting of other
preventive treatments. In the LIPID (Long-Term Intervention
With Pravastatin in Ischaemic Disease) study, compared with pa-
tients with nondetectable troponin I levels, those with troponin
I 0.18 mmol/l were 2.6 times more likely to experience a stroke,
2.4 times more likely to develop heart failure, and 2.2 times more
likely to die of cardiovascular causes. It is possible that beta-
blockers, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and other treatments that reduce blood pressure
and improve left ventricular function could have greater absolute
beneﬁts in such patients with higher risks. Troponins have been
shown to predict cardiovascular events in general population co-
horts (3), but in this setting, it is not known whether and which
treatments may reduce the risk associated with troponin elevation.We agree that current evidence suggests that, pending a cost-
effectiveness analysis, it may be reasonable to include measure-
ment of high-sensitivity troponin T or I to identify individuals at
higher risk of cardiovascular events and possibly to integrate change
in levels for dynamic risk assessment and treatment monitoring
with an increase in troponins being associated with higher risk and
a decrease with lower risk (1).
The challenge for clinicians and guideline committees is to
decide how and when to use imperfect information to inform
clinical decisionsdwhile waiting for Godotdor more reliable ev-
idence from clinical trials comparing troponin-guided treatment
with usual care in populations at modest risk based on clinical
criteriadevidence that may or may not arrive.*Harvey D. White, DSc
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